Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Creabilis has released positive results from CT327 Phase IIa examined in patients with psoriasis vulgaris.
Subscribe to our email newsletter
In the study, 48 patients were evaluated with 0.1%w/w CT327 cream twice daily and nine patients treated with matching placebo.
The study results suggested that CT327produced a good efficacy response across multiple endpoints including PGA (Physician Global Assessment) and mPASI(modified Psoriasis Area and Severity Index).
CT327 was well tolerated with no reported application site irritation. A pharmacokinetic analysis at day 56 showed there to be no measurable plasma CT327, as anticipated with the LSE technology and consistent with Phase I and pre-clinical studies.
Creabilis CEO Eliot Forster said the positive data reported today from the Phase IIa study are very promising.
"While an early stage study, we have seen good evidence of efficacy across multiple endpoints and, importantly, in PGA, the FDA’s required endpoint for psoriasis," Forster said.
"We believe our new formulation and optimised, higher, dosing will create class leading attributes for CT327. More broadly, the study provides further evidence of the potential of our LSE technology in topical drug delivery."